IS7972A - Lyfjagerð með peptíði til meðhöndlunar utan meltingarvegar á dreifðum helluroða - Google Patents

Lyfjagerð með peptíði til meðhöndlunar utan meltingarvegar á dreifðum helluroða

Info

Publication number
IS7972A
IS7972A IS7972A IS7972A IS7972A IS 7972 A IS7972 A IS 7972A IS 7972 A IS7972 A IS 7972A IS 7972 A IS7972 A IS 7972A IS 7972 A IS7972 A IS 7972A
Authority
IS
Iceland
Prior art keywords
erythema
cave
diffuse
peptide
pharmaceutical preparation
Prior art date
Application number
IS7972A
Other languages
English (en)
Inventor
Cohen-Vered Sharon
Naftali Esmira
Weinstein Vera
Gilbert Adrian
Klinger Ety
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of IS7972A publication Critical patent/IS7972A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IS7972A 2003-01-14 2005-08-05 Lyfjagerð með peptíði til meðhöndlunar utan meltingarvegar á dreifðum helluroða IS7972A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43991803P 2003-01-14 2003-01-14
PCT/US2004/000948 WO2004064787A2 (en) 2003-01-14 2004-01-14 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
IS7972A true IS7972A (is) 2006-07-15

Family

ID=32771757

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7972A IS7972A (is) 2003-01-14 2005-08-05 Lyfjagerð með peptíði til meðhöndlunar utan meltingarvegar á dreifðum helluroða

Country Status (21)

Country Link
US (3) US20050008634A1 (is)
EP (1) EP1594434B1 (is)
JP (2) JP4817068B2 (is)
KR (1) KR20050100617A (is)
CN (1) CN1774259B (is)
AU (1) AU2004206842A1 (is)
BR (1) BRPI0406745A (is)
CA (1) CA2513320C (is)
CO (1) CO5640143A2 (is)
CR (1) CR7938A (is)
DK (1) DK1594434T3 (is)
EA (1) EA009123B1 (is)
EC (1) ECSP055961A (is)
ES (1) ES2606464T3 (is)
IL (1) IL169574A (is)
IS (1) IS7972A (is)
MX (1) MXPA05007549A (is)
NO (1) NO20053773L (is)
NZ (1) NZ541658A (is)
WO (1) WO2004064787A2 (is)
ZA (1) ZA200506206B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7294687B2 (en) * 2003-01-14 2007-11-13 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
NZ541658A (en) * 2003-01-14 2008-04-30 Teva Pharma Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
EP2358395A4 (en) * 2008-11-17 2013-11-20 Hoffmann La Roche METHOD AND FORMULATION FOR REDUCING THE AGGREGATION OF A MACROMOLECULUM UNDER PHYSIOLOGICAL CONDITIONS
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
SG11201500123XA (en) * 2012-07-12 2015-02-27 Sanofi Sa Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea
CA2888822C (en) 2012-10-22 2021-01-26 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
WO2014193611A1 (en) * 2013-05-29 2014-12-04 Oklahoma Medical Research Foundation Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity
WO2015013669A1 (en) 2013-07-26 2015-01-29 The Regents Of The University Of California Mps peptides and use thereof
WO2015095789A2 (en) 2013-12-20 2015-06-25 The Regents Of The University Of California Suppression of allergic lung inflammation and hyperreactivity
JP6914188B2 (ja) 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
CA3007419A1 (en) 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
JP7242059B2 (ja) * 2017-01-05 2023-03-20 イエダ リサーチ アンド ディベロプメント カンパニー リミテッド シェーグレン症候群の治療用ペプチド
CN110476031A (zh) * 2017-04-04 2019-11-19 日东电工株式会社 冷冻干燥体的制造方法及其制造装置
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
ES2969958T3 (es) * 2017-11-30 2024-05-23 Cytogel Pharma Llc Formulaciones farmacéuticas analgésicas novedosas y usos de las mismas
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US6613536B1 (en) * 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US20020054872A1 (en) * 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
IL120503A0 (en) * 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7294687B2 (en) * 2003-01-14 2007-11-13 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
NZ541658A (en) * 2003-01-14 2008-04-30 Teva Pharma Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
US7018891B2 (en) * 2003-12-16 2006-03-28 International Business Machines Corporation Ultra-thin Si channel CMOS with improved series resistance

Also Published As

Publication number Publication date
CN1774259B (zh) 2011-12-28
CR7938A (es) 2006-05-31
CA2513320A1 (en) 2004-08-05
EA200501131A1 (ru) 2006-04-28
US20050008634A1 (en) 2005-01-13
ZA200506206B (en) 2006-12-27
ES2606464T3 (es) 2017-03-24
MXPA05007549A (es) 2006-05-19
DK1594434T3 (da) 2017-01-02
JP2011173888A (ja) 2011-09-08
NO20053773D0 (no) 2005-08-08
EA009123B1 (ru) 2007-10-26
EP1594434B1 (en) 2016-09-07
WO2004064787A3 (en) 2005-12-15
IL169574A (en) 2015-08-31
EP1594434A4 (en) 2008-09-10
ECSP055961A (es) 2006-04-19
US20130023485A1 (en) 2013-01-24
CA2513320C (en) 2018-03-27
NZ541658A (en) 2008-04-30
NO20053773L (no) 2005-10-12
KR20050100617A (ko) 2005-10-19
EP1594434A2 (en) 2005-11-16
JP4817068B2 (ja) 2011-11-16
JP2006517540A (ja) 2006-07-27
CN1774259A (zh) 2006-05-17
BRPI0406745A (pt) 2005-12-20
US20090169559A1 (en) 2009-07-02
WO2004064787A2 (en) 2004-08-05
AU2004206842A1 (en) 2004-08-05
IL169574A0 (en) 2007-07-04
CO5640143A2 (es) 2006-05-31

Similar Documents

Publication Publication Date Title
IS7972A (is) Lyfjagerð með peptíði til meðhöndlunar utan meltingarvegar á dreifðum helluroða
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
IS8363A (is) Endurbætur á bólusetningum
DK2609947T3 (da) Plasterlignende infusionsapparat
DE602004017700D1 (de) Transmukosen verabreichung
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
CY2013029I2 (el) Νεα παραγωγα ινσουλινης
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
DE602004026719D1 (de) Ür tablette
IS7946A (is) Lyf
DK1545662T3 (da) Lægemiddelindgivelsessystem
DE60315724D1 (de) Gepresste kaugummitablette
DK1599186T3 (da) System til administration af transmukalt lægemiddel
NO20052204D0 (no) Stablisert polymerblanding
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
DK1702917T3 (da) Amidderivat og medicin
DK2275439T3 (da) Hidtil ukendte insulinderivater
DE602004024999D1 (de) Thermotherapie-vorrichtung
EA200500101A1 (ru) Лекарственное средство для коррекции патологических иммунных реакций
DK1597171T3 (da) Terapeutisk mikroskum
DE602004009268D1 (de) Verbinderhalterung
NO20043576L (no) Pharmaceutical formulation comprising melatonin
IS8227A (is) Lyf
ATE546141T1 (de) Pharmazeutisches injektionspräparat
IS7971A (is) Lyfjagerð með peptíði til meðhöndlunar utan meltingarvegar á dreifðum helluroða